Powering intelligent bioanalysis

We provide the Life Science community with world-class analytical instruments and services delivering more relevant information and improved insights from bioanalysis

Validated and trusted by internationally
renowned companies and institutions

years of experience
0 +
publications enabled
0 +
drug candidates analyzed
0 +

Inbjudan till teckning
av units i Attana

Attana genomför nu en nyemission om ca 17,45 MESK av så kallade Units bestående av aktier och teckningsoptioner med företrädesrätt för befintliga aktieägare med syfte att stärka Bolagets rörelsekapital.

A proven track record of 109 assessed drug candidates

We provide the life science community with world-class analytical instruments and services for validating, selecting and optimizing drug candidates for Phase I and Phase II studies by interaction analysis of on- and off-target interactions. For our track record of 100+ analyzed candidates we have so far improved the clinical phase I and Phase II trial success rate by more than 4x.

We use cookies to improve the functionality, performance, and effectiveness of our website. Detailed information on the use of cookies is provided in our Privacy Policy and Terms of Use. By continuing to use this site, or by clicking “I agree” you consent to the use of cookies.